Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease (COPD), according to a new study.

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

Learn more about a new study that confirms the multitude of health risks associated with e-cigarettes, including COPD and ...

Chronic Obstructive Pulmonary Disease (COPD) Market. COPD market grows with rising disease prevalence, innovation in therapies, and increasing global healt ...

Nottinghamshire Healthcare’s community respiratory nurses are excited to pilot a brand new programme for patients with newly ...

When spirometry is unavailable, physicians can use the St. George’s Respiratory Questionnaire score plus peak expiratory flow ...

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

A new study published in the journal of BMC Pulmonary Medicine showed that dyspnea (mMRC score 1.67), symptom load (CAT score ...

Background Muscle wasting and weakness (sarcopenia) are commonly associated with COPD causing frailty and reduced quality of ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...